Teva Pharma (TEVA) Reports In-Line Q1 EPS, Reaffirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
Teva Pharma (TEVA) PT Lowered to $43 at Deutsche Bank
May 12, 2017 6:31 AM EDTDeutsche Bank lowered its price target on Teva Pharma (NYSE: TEVA) to $43.00 (from $45.00) while maintaining a Buy rating.
Analyst Gregg Gilbert noted TEVA reported decent 1Q results, with EPS upside driven by synergies and cost reductions that more than offset pressures... More
